
Objectives: High levels of executive dysfunction associated with attention-deficit/hyperactivity disorder (ADHD) have been linked to poorer response to pharmacotherapy. This post hoc analysis assessed the efficacy of centanafadine in the treatment of ADHD core symptoms and associated features in a subgroup of children and adolescents with high executive dysfunction. Methods: Data were pooled from two phase 3, multicenter, randomized, double-blind, placebo-controlled trials conducted in the United States and Canada in children (6–12 years) and adolescents (13–17 years) with a primary diagnosis of ADHD who received centanafadine or placebo for 6 weeks. High levels of executive dysfunction were defined using a baseline Conners 3–Parent Short Executive Function T-score of ≥70. Efficacy outcomes assessed change from baseline in ADHD core symptoms and associated features. The p values were not controlled for multiplicity. Effect sizes were calculated using Cohen’s d method based on mixed models for repeated measures estimates and are shown for outcomes that separated from placebo. Results: Among 435 participants with high executive dysfunction, baseline ADHD Rating Scale-5 (ADHD-RS-5) total scores and Conners 3–Parent Short T-scores for Inattention, Hyperactivity/Impulsivity, Defiance/Aggression, and Learning Problems were all greater than in the low dysfunction subgroup. By Week 6, ADHD-RS-5 scores in the centanafadine-treated high dysfunction subgroup were similar to those in the centanafadine-treated low dysfunction subgroup and were lower than in the placebo-treated subgroups. Over Weeks 1–6, effect sizes in the high executive dysfunction subgroup ranged from 0.35 to 0.51 for ADHD-RS-5, 0.33 to 0.56 for Conners 3–Parent Short Inattention, 0.33 to 0.43 for Hyperactivity/Impulsivity, 0.34 to 0.53 for Executive Function, 0.36 to 0.52 for Learning Problems, and 0.19 to 0.36 for Defiance/Aggression. No new safety concerns were identified. Conclusions: Individuals aged 6–17 years with high levels of executive dysfunction achieved greater improvements in ADHD core symptoms and in several associated features, including executive dysfunction and emotional dysregulation, following centanafadine treatment when compared with placebo.
Objective: To describe the feasibility, acute tolerability, and short-term symptom trajectories of adjunctive subcutaneous esketamine in adolescents with severe depressive episodes treated in specialized outpatient care.Methods: This observational case series included five adolescents aged 15-17 years with severe depressive symptoms, suicidal ideation and/or behavior, and insufficient response to previous treatments. Patients received eight once-weekly subcutaneous esketamine sessions, starting at 0.5 mg/kg and titrated up to 1.0 mg/kg based on clinical response and tolerability. Depressive symptoms were assessed using the Montgomery-& Aring;sberg Depression Rating Scale (MADRS). MADRS-rated suicidal ideation and anhedonia-related symptoms were examined descriptively using MADRS Items 10 and 8, respectively; Item 8 was considered an indirect indicator of anhedonia-related symptoms.Results: All patients completed the eight-session treatment course. Overall, MADRS trajectories were heterogeneous: one patient achieved remission, three presented varying degrees of partial improvement, and one showed no sustained benefit. MADRS Item 10 scores decreased from baseline to endpoint in four patients, and MADRS Item 8 scores decreased in four patients. Acute adverse effects included transient dissociative symptoms with mild agitation in one patient and mild transient elevations in blood pressure in some cases. No severe acute adverse events, emergency interventions, psychiatric hospitalizations, suicide attempts, or clear manic switches were documented during the 8-week protocol.Conclusions: In this small uncontrolled case series, adjunctive subcutaneous esketamine was feasible under close monitoring and was associated with heterogeneous short-term depressive symptom trajectories. Decreases in MADRS-rated suicidal ideation and MADRS Item 8 scores should be considered hypothesis-generating and do not establish antidepressant efficacy, domain-specific effects, or reduced suicide risk. Controlled pediatric studies with standardized dosing, suicide-specific assessments, systematic safety monitoring, and longer follow-up are needed.